🔎 Trials Near Me

Home › Acute Biphenotypic Leukemia › Oregon

Pag-aaral pangklinika para sa Acute Biphenotypic Leukemia sa Oregon

6 pag-aaral para sa Acute Biphenotypic Leukemia ang naghahanap ng mga kalahok sa mga site sa Oregon.

Mga Lungsod sa Oregon

Opisyal na teksto ng pag-aaral (English)

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

  • Oregon Health & Science University, Portland
Nagre-recruitPhase 1/2
30 Days · Lahat ng kasarian · Na-update Set 16, 2026 · NCT04065399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

  • Legacy Emanuel Children's Hospital, Portland
  • Oregon Health and Science University, Portland
Nagre-recruitPhase 3
365 Days – 25 Years · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT03959085

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

  • Legacy Emanuel Children's Hospital, Portland
  • Oregon Health and Science University, Portland
Nagre-recruitPhase 1/2
Hanggang edad 22 · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT04726241

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

  • Oregon Health & Science University, Portland
Nagre-recruitPhase 1/2
Edad 13 hanggang 90 · Lahat ng kasarian · Na-update Ago 6, 2026 · NCT06533579

Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

  • Oregon Health and Science University, Portland
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 7, 2026 · NCT07216443

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

  • Oregon Health & Science University, Portland
Nagre-recruitPhase 1
Edad 1 hanggang 21 · Lahat ng kasarian · Na-update Dis 6, 2024 · NCT05476770

Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.